Wednesday, October 16, 2019
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Southern Company (SO), Applied Materials (AMAT) and Vertex Pharmaceuticals (VRTX). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Southern’s shares have outperformed the Zacks Electric Power industry year to date (38.2% vs. 18.3%). The Zacks analyst believes that leveraging the demographics of its operating territories, as in healthy population and job growth, the firm has gradually increased its customer base.
With good rate base growth and constructive regulation, Southern Company is expected to generate steady earnings and dividend growth in the coming years. However, elevated leverage of the firm, along with continued timing and cost overrun issues over its Vogtle project, are the major overhangs.
While the electric utility holding company’s debt-to-capital ratio of 56% restricts financial flexibility, its $25-billion Vogtle nuclear plant has already exceeded budget and is years behind schedule. As such, Southern Company warrants a cautious stance from its investors.
(You can read the full research report on Southern here >>>)
Shares of Applied Materials have gained 20.6% in the past six months compared with the Zacks Semiconductor Equipment - Wafer Fabrication industry’s rise of 27.6%. The Zacks analyst thinks that Applied Materials is benefiting from rising need for specialty nodes in IoT, communications, automotive, power and image sensor applications. This is leading to increased customer spending in foundry and logic.
Further, the company is witnessing solid momentum across the United States and Taiwan which is a major positive. Additionally, strengthening momentum in conductor etch is aiding Applied Materials in gaining traction in DRAM and NAND. The company remains optimistic about the price elasticity of NAND, which is expected to bolster NAND customer spending in the near term.
However, market uncertainties remain headwinds. Softness in semiconductor and display markets on account of a slowdown in memory and display customers’ spending is a major concern.
(You can read the full research report on Applied Materials here >>>)
Vertex’s shares have lost 0.6% over the past three months compared with the Zacks Biomedical and Genetics industry’s decline of 4.7%. The Zacks analyst believes that Vertex’s third cystic fibrosis (CF) medicine, Symdeko, in a very short time, has become the main driver of its CF revenues.
Vertex rapidly advanced its triple combination CF regimen through late-stage development and regulatory filings. The regimen is crucial for long-term growth as it has the potential to treat up to 90% of CF patients. Meanwhile, Vertex’s non-CF pipeline, though early stage, looks interesting with several pipeline readouts expected in 2020-21.
However, competitive pressure is rising in the CF market with many other companies developing triple combo CF drugs. Also, Vertex’s dependence on just the CF franchise for growth is a concern. Shares have outperformed the industry this year so far. Estimates have gone up slightly ahead of Q3 earnings. Vertex has a positive record of earnings surprises in the recent quarters.
(You can read the full research report on Vertex here >>>)
Other noteworthy reports we are featuring today include BHP Group (BHP), NVIDIA (NVDA) and Edwards Lifesciences (EW).
Free: Zacks’ Single Best Stock Set to Double
Today you are invited to download our just-released Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.
Download Free Report Now >>
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
Southern (SO) Buoyed by Customer Growth, Vogtle Costs Hurt
Applied Materials (AMAT) Rides on Logic Spending, Risk Remain
Vertex's (VRTX) Triple Combo Cystic Fibrosis Pill Advances
NVIDIA (NVDA) Gets a Boost From Gaming Business Recovery
Per the Zacks analyst, NVIDIA is benefiting from the rising traction of GeForce laptops and RTX GPUs in the gaming market.
Edwards (EW) Rides on Solid THV Sales and Global Prospects
The Zacks analyst is bullish about Edwards' strong THV sales in the domestic and global markets.
V.F. Corp (VFC) to Gain from Solid Direct-to-Consumer Sales
Per the Zacks analyst, V.F. Corp is gaining from its direct-to-consumer business that grew 14% in first-quarter fiscal 2020.
Solid Pension Risk Transfer Business Aids Prudential (PRU)
Per the Zacks analyst, Prudential is set to grow on solid pension risk transfer business, momentum in U.S. Financial Wellness and international operations.
Organic Growth & Extensive Global Presence Aid Eaton (ETN)
Per the Zacks analyst Eaton's steady improvement in end market condition has resulted in organic growth.
Hewlett Packard (HPE) Benefits From Spurt in Aruba Services
Per the Zacks analyst, a strong uptick in Aruba Services is driving Hewlett Packard's Intelligent Edge segment.
Strategic Initiatives Aid Centene (CNC), High Costs Hurt
Per the Zacks analyst, a number of acquisitions such as that of Fidelis Care and MHM Services poise the company well for growth.
Chipotle's (CMG) Sales-Building Efforts to Drive Growth
Per the Zacks analyst, Chipotle's increased focus on food safety and enhancing customer experience, along with various sales-building and strategic initiatives bode well.
Core Health Care Products Unit Aids Fresenius Medical (FMS)
Fresenius Medical has been gaining consistently from its core Health Care Products segment. The Zacks Analyst is also optimistic about a strong view for 2019 and 2020.
Agnico Eagle (AEM) to Gain from Actions to Boost Production
The Zacks analyst is impressed by Agnico Eagle's efforts to boost its production profile and also believes that it will gain from good progress at its major growth projects.
Higher Unit Costs & Low Metal Prices to Hurt BHP Group (BHP)
The Zacks Analyst is concerned lower metal prices due to the prolonged trade war and higher unit costs due to natural field decline at petroleum and lower copper grades will impact BHP's results.
Wynn Resorts (WYNN) Grapples With High Debt Burden
Per the Zacks analyst, high debt burden makes it difficult for Wynn Resorts to finance its upcoming projects.
Plunging Natural Gas Prices to Weigh on Cabot (COG)
The Zacks analyst is concerned that the weak natural gas prices will restrict Cabot's cash flow generation considering the company's 100% gas-weighted production.
Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report
Southern Company (The) (SO) : Free Stock Analysis Report
NVIDIA Corporation (NVDA) : Free Stock Analysis Report
Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report
BHP Group Limited (BHP) : Free Stock Analysis Report
Applied Materials, Inc. (AMAT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research